The Food and Drug Administration has recorded two ‘serious’ cases in patients taking Eli Lilly’s weight-loss pill.

The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...

Eli Lilly stock recovered Monday after a patient taking its new weight-loss pill, Foundayo, experienced liver failure.

Eli Lilly stock dips after FAERS reports liver failure tied to obesity drug Foundayo (orforglipron). Read more here.

Eli Lilly (LLY) stock dropped 3% on Foundayo liver concerns. Analysts say the decline is overdone and recommend buying the ...

Eli Lilly is seeing its stock come under pressure after a report linked a case of liver failure to its newly launched weight loss pill Fo ...

A solitary entry in a federal adverse-event database was enough to knock nearly $15 off Eli Lilly’s share price on Monday, but the selloff proved fleeting. Within hours, the stock had clawed back into ...

Eli Lilly shares dipped about 1% on Monday morning after U.S. regulators logged a serious adverse-event report involving the company's ne ...

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to invest in before they split next. Truist Securities restated its Buy ...

A clinical trial result presented almost as an aside in Eli Lilly’s latest earnings report dropped like a bomb this week on the biotechs developing treatments for the liver condition known as MASH.